JAZZ News and Press, Jazz Pharmaceuticals plc From 11/05/19

Jazz Pharmaceuticals (NASDAQ: JAZZ ): Q3 Non-GAAP EPS of $4.10 beats by $0.51 ; GAAP EPS of $1.78 misses by $0.32 . Revenue of $537.7M (+14.6% Y/Y) beats by $13.78M . Shares +5.6% . Press Release More news on: Jazz Pharmaceuticals plc, Earnings news and commentary, Stocks on th...

Total Revenues Increased 15% to $538 Million GAAP Diluted EPS of $1.78 ; Adjusted Diluted EPS of $4.10 2019 Total Revenues Guidance Increased to $2.10- $2.18 Billion , an Increase of 11-15% Over 2018 2019 EPS Guidance Updated to $8.00- $9 .00 on a GAAP Basis,...

DUBLIN , Oct. 22, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 third quarter financial results on Tuesday, November 5, 2019 , after the close of the financial markets. Company management will host a live audio webcast...

Allergan (NYSE: AGN ) resumed with Market Perform rating and $180 (7% upside) price target at Bernstein. More news on: Allergan plc, Amgen Inc., Biogen Inc., Healthcare stocks news, Stocks on the move, , Read more ...

The first participant has been enrolled in an exploratory Phase 2 clinical trial evaluating Jazz Pharmaceuticals' (NASDAQ: JAZZ ) defibrotide for the prevention of neurotoxicity in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) receiving Gilead Sciences' (NASDAQ:...

DUBLIN , Oct. 10, 2019 /PRNewswire/ --   Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in an exploratory Phase 2 clinical trial evaluating the ability of defibrotide to prevent neurotoxicity in patients with relapsed or refractory di...

DUBLIN , Sept. 30, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the results of a consumer survey of more than 1,000 Americans measuring public perception and knowledge of sleep disorders like narcolepsy. Narcolepsy is a serious condition that is often ...

Results from a Phase 1 proof-of-concept study evaluating Takeda Pharmaceutical's (NYSE: TAK ) TAK-925, a selective orexin type-2 receptor (OX2R) agonist, in patients with narcolepsy type 1 (NT1) showed a treatment effect. The data were presented at the World Sleep Congress in Vancouver. ...

DUBLIN , Sept. 25, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that positive data from the Phase 3 study of its investigational medicine, JZP-258, for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adults with narcolepsy were ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...